speaker
Operator
Conference Operator

Welcome to the Solaris Pharmaceuticals Second Quarter 2022 Financial Results and Business Update Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then 2. Please note, this event is being recorded. I would now like to turn the conference over to Kim Golodets with LHA Investor Relations. Kim, please go ahead.

speaker
Kim Golodets
Senior Vice President Principal, LHA Investor Relations

Thank you. This is Kim Golodets, Senior Vice President Principal with LHA Investor Relations. Thank you all for participating in today's call. Joining me from Solaris Pharmaceuticals are David Arthur, Director and Chief Executive Officer, and Mark Rosenblum, Chief Financial Officer. In addition, Dr. Daniela Santay-Esteban, Director of Protein Degradation Development, will be available for Q&A. During this call, Solaris will be making forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about its strategy, future operations, the development and effectiveness of its investigational drug candidates, Seclodemstat and SP3164, as well as its targeted protein degradation program and expectations regarding its capital allocation and cash resources. These statements are based on Solaris' current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to risks and uncertainties, including those detailed in the risk factor section of the company's annual report on Form 10-K for the year ended December 31, 2021. and subsequent quarterly reports on Form 10-Q, as well as other periodic SEC filings. Except as required by law, Solaris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. With that said, I'd like to turn the call over to David Arthur, CEO of Solaris Pharmaceuticals. David?

speaker
David Arthur
Director and Chief Executive Officer, Solaris Pharmaceuticals

Thank you, Kim. And thank you to all of you for joining this call and for your interest in Solaris, particularly for all of you joining us for your first Solaris earnings and business call update. The second quarter and recent weeks were once again very productive for Solaris as we continue to advance both of our lead programs towards multiple near-term milestones. We are making excellent progress in pursuit of our vision of treating patients fighting cancer with either seclidemstat or SP3164, while providing investors with potential value-creating inflection points later this year. Indeed, based on the progress we made in the first half of this year, we expect a busy second half of 2022. I'll first talk about seclidemstat, our reversible LSD1 protein inhibitor. And although seclidemstat program is furthest along the development path That does not in any way diminish the excitement we have for 3164, our targeted protein degrader, where we plan to submit an investigational new drug application to the FDA and begin human trials next year. Enrollment in our Phase 1-2 study with seclidemstat in Ewing's and other FET-rearranged sarcomas is progressing well. Last week, we announced the addition of several prestigious sites to the study. the Seattle Cancer Care Alliance, which is comprised of the Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, and the University of Washington Medical Center, all well-known names in cancer research. We also added Oregon Health and Sciences University, another well-known name, which brings us to 15 total clinical sites representing 23 separate locations around the country enrolling patients. We also plan to add a few more sites in the coming weeks and plan to make an announcement once those sites are active. We remain on track to report interim data later this year with additional data being available as patients continue to enroll and continue on ceclodemstat treatment. As a reminder, Ewing's and FET rearranged sarcomas are rare with limited treatment options and poor prognosis, which makes the work we do extremely important. All of us at Solaris, and hopefully you as investors and interested parties, are motivated by the prospect of making a difference in the treatment of these cancers with high unmet needs. We are also excited to announce last week a collaboration with VolitionRx to advance rapid epigenetic profiling utilizing their NQ technology. This profiling will support further development of seclidemstat by studying biomarkers to allow for a non-invasive method of determining target engagement. In other words, is the drug reaching and having activity in patients' cancer cells? So, this exciting research collaboration provides us another tool to aid in the development of seclidemstat to treat patients in the clinic and beyond. The study of seclidemstat is also progressing at the MD Anderson Cancer Center in an investigator-initiated hematologic or blood cancer clinical trials. As a reminder, the cost of investigator-initiated clinical trials is usually significantly subsidized by the sponsoring institution, which in this case is MD Anderson, which markedly reduces the cost to generate key proof-of-concept patient data. We continue to expect interim clinical updates from this trial before the end of the year. Now, turning to our Protein Degradator Act Set, SP 3164. Recall that in January of this year, we acquired an intellectual property portfolio from Duterex LLC, including the drug candidate SP 3164. 3164 now forms the basis of our Targeted Protein Degradation, or TPD, drug development program. TPD is the subject of heightened interest in the pharmaceutical community because of its potential to develop medicines that target cancer-promoting proteins that have historically been considered undruggable. In addition, we believe this is a validated area of cancer research, with a class of early protein degraders called molecular glues showing considerable therapeutic and commercial success. Let's not forget, The Bristol-Myers Squibb reported in their fourth quarter and full year financial results for 2021 that the first generation molecular glues Revlimid and Pomalyst generated over $16 billion in global sales in 2021. As I just mentioned, we believe this helps explain heightened interest in protein degradation among the pharmaceutical community. What we believe makes 3164 unique or differentiated from other molecular glues is that it is the preferred half or preferred enantiomer of the widely studied drug of atomide, with the potential for increased efficacy and improved safety versus of atomide and potentially other molecular glues. Since its acquisition at the beginning of the year, we have made good progress in advancing 3164 and have already completed the pre-IND meeting process with the FDA. That meeting process provided valuable input and clarity on preclinical, clinical, and other regulatory matters for preparing and submitting our IND. We are currently implementing IND-enabling studies and other development activities, and we believe we remain on track for an IND submission in the first half of next year, with the start of clinical studies soon thereafter. Included in our IND-enabling work are studies evaluating 3164 as single-agent treatment, used in combination with other common anti-cancer treatments, and compared to other molecular glues, and we continue to look forward to providing updates later this year. Many large pharma companies are partnering with development-stage protein-degrader companies. likely catalyzed by the commercial success of first molecular glues like Revlimid and Pomalyst, which, as I mentioned earlier, had 2021 global sales of more than $16 billion. As a reminder, we have seen a large number of partnerships for both preclinical and early clinical stage drugs, including most recently in February when Amgen signed a development deal for Plexium's protein degrader valued at more than $100 million. We were interested in hearing from pharmaceutical leaders with respect to both 3164 and secludemstat, and with that in mind, we attended the 2022 Bio International Conference in San Diego, California. With over 15,000 attendees, Bio provided members of the Solaris team with multiple opportunities to provide updates not only on both programs, but to capture input on what type of preclinical and clinical data a number of those pharmaceutical companies would like us to generate. We've taken that advice, so we consider Bio a success. Before I turn the call over to Mark to review our second quarter and year-to-date financial results, I want to add that we have managed our expenses very well while progressing towards our 2022 milestones. Each day draws us closer to achieving those milestones and potentially having two anti-cancer medicines to treat patients who have failed existing therapies. Mark, over to you.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-